DE3142590A1 - Verwendung von biotin zur behandlung der zuckerkrankheit - Google Patents
Verwendung von biotin zur behandlung der zuckerkrankheitInfo
- Publication number
- DE3142590A1 DE3142590A1 DE19813142590 DE3142590A DE3142590A1 DE 3142590 A1 DE3142590 A1 DE 3142590A1 DE 19813142590 DE19813142590 DE 19813142590 DE 3142590 A DE3142590 A DE 3142590A DE 3142590 A1 DE3142590 A1 DE 3142590A1
- Authority
- DE
- Germany
- Prior art keywords
- biotin
- insulin
- glucose
- serum
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title claims description 357
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 37
- 239000011616 biotin Substances 0.000 title description 154
- 229960002685 biotin Drugs 0.000 title description 154
- 235000020958 biotin Nutrition 0.000 title description 153
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 169
- 229940125396 insulin Drugs 0.000 claims description 85
- 102000004877 Insulin Human genes 0.000 claims description 84
- 108090001061 Insulin Proteins 0.000 claims description 84
- 238000011282 treatment Methods 0.000 claims description 44
- 235000000638 D-biotin Nutrition 0.000 claims description 25
- 239000011665 D-biotin Substances 0.000 claims description 25
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 74
- 239000008103 glucose Substances 0.000 description 74
- 210000002966 serum Anatomy 0.000 description 48
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 40
- 210000002700 urine Anatomy 0.000 description 23
- 238000002560 therapeutic procedure Methods 0.000 description 21
- 239000000902 placebo Substances 0.000 description 19
- 229940068196 placebo Drugs 0.000 description 19
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 15
- 230000004044 response Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000012417 linear regression Methods 0.000 description 8
- 206010018473 Glycosuria Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 239000002933 immunoreactive insulin Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 238000003359 percent control normalization Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 206010004906 Biotin deficiency Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010052805 Drug tolerance decreased Diseases 0.000 description 1
- 206010052806 Drug tolerance increased Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 229940079172 Osmotic diuretic Drugs 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013569 fruit product Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000002337 osmotic diuretic agent Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000033882 response to biotin Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20078480A | 1980-10-27 | 1980-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3142590A1 true DE3142590A1 (de) | 1982-08-12 |
Family
ID=22743169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19813142590 Withdrawn DE3142590A1 (de) | 1980-10-27 | 1981-10-27 | Verwendung von biotin zur behandlung der zuckerkrankheit |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS5799520A (enrdf_load_stackoverflow) |
| AU (1) | AU7683381A (enrdf_load_stackoverflow) |
| BE (1) | BE890888A (enrdf_load_stackoverflow) |
| DE (1) | DE3142590A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2492662A1 (enrdf_load_stackoverflow) |
| NL (1) | NL8104818A (enrdf_load_stackoverflow) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE19855T1 (de) * | 1982-03-01 | 1986-06-15 | Efamol Ltd | Pharmazeutische und diaetetische zusammensetzung. |
| AU2003266287A1 (en) * | 2002-08-23 | 2004-03-11 | Dsm Ip Assets B.V. | Novel nutraceutical compositions comprising biotin |
| JP2004203863A (ja) * | 2002-12-09 | 2004-07-22 | Taisho Pharmaceut Co Ltd | 抗糖尿病用組成物 |
| JP2006089392A (ja) * | 2004-09-22 | 2006-04-06 | Tohoku Univ | 生活習慣病改善食品および生活習慣病治療薬 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE788779A (fr) * | 1971-09-13 | 1973-01-02 | Magnor Inc | Produit a base de biotine pour le traitement du diabete |
-
1981
- 1981-10-26 NL NL8104818A patent/NL8104818A/nl not_active Application Discontinuation
- 1981-10-26 AU AU76833/81A patent/AU7683381A/en not_active Abandoned
- 1981-10-27 JP JP56171944A patent/JPS5799520A/ja active Pending
- 1981-10-27 FR FR8120147A patent/FR2492662A1/fr active Granted
- 1981-10-27 BE BE0/206366A patent/BE890888A/fr not_active IP Right Cessation
- 1981-10-27 DE DE19813142590 patent/DE3142590A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| FR2492662A1 (fr) | 1982-04-30 |
| BE890888A (fr) | 1982-02-15 |
| NL8104818A (nl) | 1982-05-17 |
| AU7683381A (en) | 1982-05-06 |
| JPS5799520A (en) | 1982-06-21 |
| FR2492662B1 (enrdf_load_stackoverflow) | 1985-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3856018T2 (de) | Verwendung von einer Disaccharidpolysulfat-Aluminium Verbindung zur Herstellung eines Medikaments zur Behandlung von HÄMORRHOIDEN und zur Wundheilung | |
| EP1162995B1 (de) | Enzyme zur behandlung von diabetes mellitus typ i | |
| DE69624580T2 (de) | Verfahren und zusammensetzung zur verbesserten parenteralen ernährung | |
| DE60127827T2 (de) | Verwendung von einem insulin-sensibilisator in der behandlung von alopecia | |
| DE69731386T2 (de) | Verfahren zur behandlung von asthma mit o-desulfatisiertem heparin | |
| DE69624699T2 (de) | Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes | |
| EP2099462B1 (de) | Pharmazeutische zubereitung für die behandlung entzündlicher erkrankungen des urogenitaltraktes | |
| DE69022501T2 (de) | Verwendung eines Amylinantagonisten zur Herstellung eines Artzneimittels zur Behandlung von Fettsucht und essentieller Hypertonie und damit zusammenhängenden Krankheiten. | |
| EP0326034A2 (de) | Kombinationspräparat zur Behandlung von Nervenzell-und Nervenfasererkrankungen und Verletzungen | |
| CH653891A5 (de) | Mittel fuer die orale verabreichung an einen menschen und/oder ein saeugetier. | |
| DE3338995A1 (de) | Bilobalid enthaltende arzneimittel | |
| Eddouks et al. | Hypoglycaemic effect of Triticum repens P. Beauv. in normal and diabetic rats | |
| DE3446886A1 (de) | Mittel zur behandlung von fettsucht | |
| CH654211A5 (de) | Arzneimittel zur behandlung von diabetes mellitus. | |
| CH672987A5 (enrdf_load_stackoverflow) | ||
| DE69715841T2 (de) | Phosphatidsäure enthaltende zusammensetzungen | |
| DE4214953A1 (de) | Arzneimittel zur Erhöhung des Testosteronspiegels | |
| DE4136215A1 (de) | Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie | |
| DE3232033A1 (de) | Pharmazeutisches mittel | |
| DE602004005455T2 (de) | Verfahren zur behandlung oder prävention von chronischen wunden und komplette nahrungszusammensetzung mit glycin und/oder leucin zur verwendung darin | |
| DE4413839C1 (de) | Kombinationspräparat | |
| DE3142590A1 (de) | Verwendung von biotin zur behandlung der zuckerkrankheit | |
| DE60017251T2 (de) | Kombination der nikotinsäure oder nikotinamid mit riboflavin für die behandlung der pruritus und entzündungstörungen | |
| DE2660486C2 (de) | Verwendung von 2-Hydroxymethyl-3,4,5-trihydroxypiperidin als Arzneimittel | |
| DE69821970T2 (de) | Verwendung von CITICOLINE ZUR BEHANDLUNG VON MULTIPLER SKLEROSE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |